GoAI
Get started
AEON Biopharma, Inc. logo

AEON Biopharma, Inc.

AEON

AMEXHealthcareBiotechnology

Open in GoAI

Regular session

$0.1933

+$0.0012 · +0.62%

Aug 24, 2:31 PM ET

AEON company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

60

Fair Value

Momentum

21

Weakening

Sentiment

51

Mixed

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Robert Bancroft
Listed since
Jul 24, 2023
Employees
8

Market position

Day range

Current $0.1933

52-week range

Current $0.1933

Open
$0.201
Previous close
$0.1921
Volume
705.46K
0.57× average
Average volume
1.23M
Average daily volume
Market cap
8.54M USD
Beta
0.64
Market reference 1
50-day average
$0.4342
-55.49% below average
200-day average
$0.8445
-77.11% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.04×
P/B (TTM)
-0.64×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
-0.18×
Altman Z-score
-129.42
Piotroski F-score
2 of 9

Financial statements

Income trends

Operating income

−12.8M USD−85.79M USD

Net income

−39.22M USD−81.23M USD
Income trends across reported periods118.75M USD−64.3M USD−247.35M USD−430.39M USDOperating income, FY2021: −65.85M USDOperating income, FY2022: −48.43M USDOperating income, FY2023: −348.09M USDOperating income, FY2024: 72.99M USDOperating income, FY2025: −12.8M USDNet income, FY2021: −55.64M USDNet income, FY2022: −52.56M USDNet income, FY2023: −384.63M USDNet income, FY2024: 42.01M USDNet income, FY2025: −39.22M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −65.85M USD. Operating income FY2022 −48.43M USD. Operating income FY2023 −348.09M USD. Operating income FY2024 72.99M USD. Operating income FY2025 −12.8M USD. Net income FY2021 −55.64M USD. Net income FY2022 −52.56M USD. Net income FY2023 −384.63M USD. Net income FY2024 42.01M USD. Net income FY2025 −39.22M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development4.09M USD14.18M USD33.05M USD34.75M USD25.73M USD
Selling, general, and administrative12.21M USD13.64M USD19.79M USD13.68M USD11.15M USD
Operating expenses12.8M USD−72.99M USD348.09M USD48.43M USD65.85M USD
Depreciation and amortization78K USD97K USD99K USD68K USD3K USD
Operating income−12.8M USD72.99M USD−348.09M USD−48.43M USD−65.85M USD
Net income−39.22M USD42.01M USD−384.63M USD−52.56M USD−55.64M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 2 misses, 2 met estimates
Average EPS surprise
-235.78%
11 comparable reports
Latest EPS result
-0.02
Estimate -0.23 · Beat by 91.11%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates5.14-1.59-8.33-15.06Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 24, 2025: actual 3.75, estimate -12.95, surprise +128.96%, Beat. Q2 2025, reported May 14, 2025: actual 2.28, estimate -13.67, surprise +116.68%, Beat. Q3 2025, reported Aug 11, 2025: actual -0.6, estimate -11.51, surprise +94.79%, Beat. Q4 2025, reported Nov 14, 2025: actual -0.39, estimate -0.43, surprise +9.30%, Beat. Q1 2026, reported Mar 30, 2026: actual -5.24, estimate -0.17, surprise -2982.35%, Miss. Q2 2026, reported May 14, 2026: actual -0.44, estimate -0.44, surprise 0.00%, Met estimate. Q3 2026, reported Aug 12, 2026: actual -0.02, estimate -0.225, surprise +91.11%, Beat. Q4 2026, reported Nov 13, 2026: actual —, estimate -0.07, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

2 institutions
Aegis CapitalmaintainBuy

AEON news

globenewswire.com

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

- Former Deputy Director of the FDA's Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450…

Read source
globenewswire.com

AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®

- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed

Read source
globenewswire.com

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program

Read source
globenewswire.com

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA)…

Read source
globenewswire.com

Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards

VICTORIA, Seychelles, July 27, 2026 (GLOBE NEWSWIRE) -- Bitget , the world's largest Universal Exchange (UEX), announced the addition of AEON (AEON) to Bitget Launchpool and spot market. Spot trading for the AEON/USDT…

Read source
globenewswire.com

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding

$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering $13.75 million underwritten…

Read source

AEON peers

National HealthCare Corporation logo

NHC

National HealthCare Corporation

$229.83

-1.53%

Perspective Therapeutics, Inc. logo

CATX

Perspective Therapeutics, Inc.

$3.205

-2.88%

Electromed, Inc. logo

ELMD

Electromed, Inc.

$39.985

+1.36%

Lineage Cell Therapeutics, Inc. logo

LCTX

Lineage Cell Therapeutics, Inc.

$1.085

+0.46%

InfuSystem Holdings, Inc. logo

INFU

InfuSystem Holdings, Inc.

$11.985

-1.84%

Protalix BioTherapeutics, Inc. logo

PLX

Protalix BioTherapeutics, Inc.

$2.375

-0.21%

ETFs holding AEON

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR Portfolio Emerging Markets ETF logoState Street SPDR Portfolio Emerging Markets ETFSPEM
Market value
3.39M
Weight
0.02%
AUM
17.57B USD
Expense ratio
0.07%
Price / 1D
$52.02-0.69%
State Street SPDR S&P Emerging Markets Small Cap ETF logoState Street SPDR S&P Emerging Markets Small Cap ETFEWX
Market value
93.73K
Weight
0.01%
AUM
685.65M USD
Expense ratio
0.65%
Price / 1D
$71.625-0.74%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
26.53K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.71-0.74%

Continue in GoAI

Research AEON

research.disclaimer